title: Effects of short-term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia.
abstract: To evaluate the effects of short-term cholesterol-lowering treatment on myocardial effort ischemia, 22 patients with stable effort ischemia and mild to moderate hypercholesterolemia (low density lipoprotein [LDL] cholesterol 160 to 220 mg/dl) were randomly allocated at baseline (TO) in 2 groups. Group A included 12 patients treated with simvastatin 10 mg bid; group B included 10 patients treated with placebo. All patients underwent a treadmill electrocardiography (ECG) test; total cholesterol, HDL and LDL cholesterol, triglycerides, plasma, and blood viscosity were measured. All tests were repeated after 4 and 12 weeks. For 18 of the same patients (11 taking simvastatin, 7 receiving placebo), forearm strain-gouge plethysmography was performed at baseline and after 4 weeks, both at rest and during reactive hyperemia. At 4 and 12 weeks, group A showed a significant reduction in total cholesterol (p <0.05) and LDL (p <0.05), with unchanged HDL, triglycerides, blood, and plasma viscosity. Effort was unmodified, ST-segment depression at peak effort and ischemic threshold were significantly improved after 4 and 12 weeks (all p <0.05) with unchanged heart rate x systolic blood pressure product. A significant increase in the excess flow response to reactive hyperemia was detected in group A (p <0.03); group B showed no changes in hematochemical and ergometric parameters. These data suggest that cholesterol-lowering treatment is associated with an improvement in myocardial effort ischemia; this might be explained by a more pronounced increase of coronary blood flow and capacity of vasodilation in response to effort.
authors.affiliation: Institute of Cardiology of Second University of Naples, Italy.
authors.forename: M
authors.initials: M
authors.lastname: de Divitiis
authors.forename: P
authors.initials: P
authors.lastname: Rubba
authors.forename: S
authors.initials: S
authors.lastname: Di Somma
authors.forename: V
authors.initials: V
authors.lastname: Liguori
authors.forename: M
authors.initials: M
authors.lastname: Galderisi
authors.forename: S
authors.initials: S
authors.lastname: Montefusco
authors.forename: G
authors.initials: G
authors.lastname: Carreras
authors.forename: V
authors.initials: V
authors.lastname: Greco
authors.forename: A
authors.initials: A
authors.lastname: Carotenuto
authors.forename: G
authors.initials: G
authors.lastname: Iannuzzo
authors.forename: O
authors.initials: O
authors.lastname: de Divitiis
mesh_terms: D000704:Analysis of Variance; D000787:Angina Pectoris / Q000150:complications* / Q000503:physiopathology; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D004562:Electrocardiography; D005080:Exercise Test; D005542:Forearm / Q000098:blood supply; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects; D019821:Simvastatin; D016037:Single-Blind Method
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin